Search

The conference was organised by the UAI (Innovation Support Unit) of the IiSGM (Instituto de Investigación Sanitaria Gregorio Marañón) and was sponsored by GENESIS Biomed, HOFFMANN EITLE and supported

Being this said, at Biobide they have published a new scientific research where it has been validated the Thyroid Disruption (TD) Assay in zebrafish embryos by fluorescence image analysis utilizing

"A forthcoming initiative will help materialize all the benefits of biotechnologies and biomanufacturing, key elements for the competitiveness and modernization of the European Union's industry due to

This momentousinvestment will serve as the catalyst for revolutionizing the landscape of living single cellanalysis.

Spark secures exclusive worldwide rights to SpliceBio’s proprietary Protein Splicing platform to develop, manufacture, and commercialize a gene therapy targeting an undisclosed inherited retinal

At AseBio, we believe that it is crucial to reposition the biotechnology sector as a strategic industry. However, to achieve this, the collaboration of political and social efforts is essential.

The acquisition of aidhere strengthens Sidekick Health’s digital health offering to patients and partners with the world’s leading PDT company

At the 36th European College of Neuropsychopharmacology congress (ECNP-2023).

During the 5th and 6th of October 2023, Granada hosted meetings of the European Political Community (EPC) and the heads of state or government of the EU, where the strategic priorities for the future

The operation was led by the Mind the Gap program from Botín Foundation, with participation from GENESIS Ventures and the Eurostars program.

The European Innovation Council (EIC) Fund and the Alzheimer's Drug Discovery Foundation (ADDF) Diagnostic Accelerator (DxA) join the round, alongside other investors such as Lavanda Ventures, Ship2B

Meet ProductLife Group, our new partner. We spoke with Wendy Morales, business development manager.

Researchers at Nostrum Biodiscovery, with the collaboration of other companies, have laid the groundwork for the systematic development of optimal RNA-binding inhibitors based on antisense

Studies indicate that more than 60 percent of medication errors are caused by mistakes in interpersonal communication.